Security key
090628306
BioNexus Gene Lab Corp - Common Stock, no par value (BGLC)
CUSIP: 090628306
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, no par value
- Total 13F shares
- 14,385
- Total 13F value
- $27,199
- Share change
- +14,153
- SEC-reported price per share
- $1.95
- Number of holders
- 3
- Value change
- +$26,746
- Number of buys
- 2
- Number of sells
- 2
- Shares outstanding
- 2,945,296
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
BGLC full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
BioNexus Gene Lab Corp SEC filings
BioNexus Gene Lab Corp company facts
Broader feeds
Reporting periods
Holder history for CUSIP 090628306
Recent filing periods:
Ownership snapshot
Top reported holders of BGLC - BioNexus Gene Lab Corp - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FIDELION DIAGNOSTICS PTE....
Disclosed value leader
FIDELION DIAGNOSTICS PTE....
Comparable rows
3/5
Latest evidence
31 Mar 2026
3/4/5
13F
Lead comparable stake: 13%
2 rows are not safely comparable across share classes.
Quick read
FIDELION DIAGNOSTICS PTE. LTD. leads the comparable SEC ownership view at 13%.
3 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FIDELION DIAGNOSTICS PTE. LTD.'s linked filing trail.
Comparable ownership
Top 3
FIDELION DIAGNOSTICS PTE. LTD.
13%
UBS Group AG
0.01%
WELLS FARGO & COMPANY/MN
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-5 of 5 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FIDELION DIAGNOSTICS PTE. LTD. |
3/4/5
Greater than 5% holder
|
13%
|
$839,584
392,329 shares
|
— | 28 Nov 2025 |
| UBS Group AG |
13F
Company
|
0.01%
|
$495
231 shares
|
— | 31 Mar 2026 |
| WELLS FARGO & COMPANY/MN |
13F
Company
|
0%
|
$2
1 shares
|
— | 31 Mar 2026 |
| Tai Tan Liong |
3/4/5
Chief Operating Officer, Director
|
—
class O/S missing
|
—
12,500,460 shares
|
— | 19 Jul 2023 |
| Wei Li Leong |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
—
4,797,709 shares
|
— | 19 Jul 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
14,385
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
2
Q2 2026 holders
3
Holder diff
1
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend